Equities

Kazia Therapeutics Ltd

KZIA:NAQ

Kazia Therapeutics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.79
  • Today's Change0.26 / 4.70%
  • Shares traded5.74k
  • 1 Year change-17.29%
  • Beta2.0091
Data delayed at least 15 minutes, as of Nov 22 2024 15:26 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Kazia Therapeutics Ltd grew revenues 979.43% from 2.09k to 22.56k while net income improved from a loss of 25.01m to a smaller loss of 20.47m.
Gross margin--
Net profit margin-90,714.45%
Operating margin-91,918.53%
Return on assets-63.98%
Return on equity-134.97%
Return on investment-82.39%
More ▼

Cash flow in AUDView more

In 2023, cash reserves at Kazia Therapeutics Ltd fell by 2.12m. Cash Flow from Financing totalled 12.97m or 57,500.00% of revenues. In addition the company used 15.16m for operations while cash from investing was breakeven.
Cash flow per share--
Price/Cash flow per share--
Book value per share34.41
Tangible book value per share-14.90
More ▼

Balance sheet in AUDView more

Kazia Therapeutics Ltd has a Debt to Total Capital ratio of 12.97%.
Current ratio1.42
Quick ratio--
Total debt/total equity0.1491
Total debt/total capital0.1297
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.